tbuckley/cabot-search huggingface dataset:
THU0036 The effect of infliximab on plasma lipoproteins
Authors: MM Spak, EC Cauza, KC Cauza, UH Hanusch-Enserer, AD Dunky, KK Kostner
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> We investigated the effect of Infliximab, a mouse-human chimaeric monoclonal antibody that binds and inhibits the activity of TNF a, on Lipid Metabolism in patients with Rheumatoid arthritis (RA) and Psoriatic arthritis (Psa). <h3>Objectives</h3> <h3>Methods</h3> Fifteen persons hospitalised in our division of rheumatology were studied. Over a period of eight months 5 male and 10 female patients with a mean age of 56,7 years (age range: 30–81) were included in this study. The subjects included 7 patients with rheumatoid arthritis (RA) according to the ARA criteria (12) and 8 patients with Psoriatic arthritis (PsA). Eight patients had been treated with methotrexat (MTX), 4 with other DMARDs than MTX, 2 patients only received NSAIDs and 5 corticosteroids. Treatment resistant patients with active disease (fulfilling inclusions criteria) received infusions of 3 mg/kg infliximab (at week 0, 2, 6 14, 22 and 30). Two of the patients received 4 mg/kg infliximab after 14 weeks. Lipoprotein (a), Cholesterol, triglycerides, LDL-cholesterol and HDL-cholesterol were measured by commercially available kits from Boehringer Mannheim (Mannheim, Germany). <h3>Results</h3> Infliximab was well tolerated; no toxic effects were observed, no major abnormalities in hematologic findings were noted during or after the study. There was no significant difference either in total cholesterol before and after treatment (209 ± 25 vs. 25 ± 36 mg/dl) or in LDL-cholesterol (1311 ± 24 vs. 1188 ± 4 mg/dl). Lp (a) levels also did not show a change during treatment (median: 1,1 vs. 1,4 mg/dl). However there was a significant rise in triglyceride (TG) levels during treatment with Remicade (1122 ± 48 vs. 1333 ± 5 mg/dl, p &lt; 0.01). HDL levels on the other hand were significantly lowered (566 ± 12 vs. 50 ± 1 mg (dl, p &lt; 0.006) by the treatment. The changes of the main parameters are summarised in Table 1. <h3>Conclusion</h3> This study shows that elevated TG and decreased HDL levels occur in patients with RA and PsA after Infliximab therapy. We suggest that these changes in lipid metabolism may be a factor responsible for an increased development of vascular pathology.
Index of Bone Marrow Output and Imbalance of B-Lymphocyte Homeostasis before and after Transplantation Correlate Differently with Graft-Versus-Host Disease and Relapse
Authors: Crisitina Skert, Simone Perucca, Imberti Luisa, Chiarini Marco, Michele Malagola, Carla Filì, Viviana Giustini, Claudia Ghidini, Federica Cattina, Alessandro Turra, Valeria Cancelli, Simona Bernardi, Domenico Russo
Journal: Blood (2015)
Red and processed meat, and human and planetary health
Authors: John D Potter
Journal: BMJ (2017)

Contemporary meat consumption harms human health and is equally bad for the planet

Analyses from the National Institutes of Health (NIH)-AARP study have previously shown that mortality was higher among participants with a high meat intake. With a total of more than 7.5 million person years of observation, further analyses by Etemadi and colleagues (doi:10.1136/bmj.j1957) now show an association between high intakes of red and processed meat and elevated total mortality and mortality from most major causes: cardiovascular disease, diabetes, cancer, and hepatic, renal, and respiratory diseases.1 They have explored the possible role of meat constituents and established that both haem iron (from red meat) and nitrate/nitrite (from processed meats) provide explanatory power and, perhaps, information on causation. The fact that poultry and fish intake are inversely related to risk and contain little of these agents adds plausibility to their causal interpretation.

The problem is, however, that red and processed meats are likely to be harmful to human health in many different ways, often linked to more than one outcome. Simply choosing one or two from a list …
Highly Efficient Virus Rejection with Self‐Organized Membranes Based on a Crosslinked Bicontinuous Cubic Liquid Crystal
Authors: Nicolas Marets, Daniel Kuo, Jason R. Torrey, Takeshi Sakamoto, Masahiro Henmi, Hiroyuki Katayama, Takashi Kato
Journal: Advanced Healthcare Materials (2017)

To remove viruses from water, the use of self‐assembling liquid crystals is presented as a novel method for the synthesis of membranes with a regular pore size (below 1 nm) and controlled pore structures. Nanostructured bicontinuous cubic liquid‐crystalline (LC) thin films are photopolymerized onto a polysulfone support layer. It is found that these membranes reject the virus, Qβ bacteriophage (≈20 nm diameter) by &gt;99.9999%. Prepressurization of the membrane appears to enhance their virus rejection properties. This is the first example of nanostructured LC membranes that are used for virus rejection, for which they show great potential.
Incorrect Definition in Abstract
Authors: Claudia Van Borkulo, Denny Borsboom, Robert Schoevers
Journal: JAMA Psychiatry (2016)

Katherine L. Musliner, PhD; Trine Munk-Olsen, PhD; Thomas M. Laursen, PhD; William W. Eaton, PhD; Peter P. Zandi, PhD; Preben B. Mortensen, DrMedSc
Abstract 219: Diabetes-induced Mitochondrial Dna Damage and Cardiac Dysfunction are Aggravated Due to Low Aldehyde Dehydrogenase 2 (aldh2) Activity in Aldh 2*2 (e487k) Knock-in Mutant Mice
Authors: Suresh S Palaniyandi, Gudong Pan, Mandar Deshpande, Vishal R Mali, Jiang Xu, Xiao-Ping Yang, Shailendra Giri, Che-Hong Chen, Daria Mochly-Rosen
Journal: Circulation Research (2015)

A prevalent mutation (E487K) in aldehyde dehydrogenase (ALDH) 2, a cardiac mitochondrial enzyme, in East Asians (ALDH2*2) reduces ALDH2 activity and thereby increases aldehyde toxicity. Decreased ALDH2 activity is associated with cardiovascular diseases in humans and animal models. In this study, we hypothesized that reduction in ALDH2 activity in ALDH2*2 mice is sufficient to increase 4-hydroxy-2-nonenal (4HNE) levels and impair mitochondrial respiration and consequently induce cardiac damage in diabetes mellitus (DM). To test the hypothesis, streptozotocin (150 mg/kg i.p.) injected type-1 diabetic ALDH2*2 and C57BL mice as well as corresponding non-diabetic mice were employed. Four experimental groups were C57BL Control, C57BL DM, ALDH2*2 Control, and ALDH2*2 DM. N=6. Data were presented below in the same order. The mice were sacrificed after 3 weeks of DM. Myocardial ALDH2 activity and levels were reduced and 4HNE protein adducts were increased in ALDH2*2 DM mice relative to C57BL DM mice. Decrease in mitochondrial respiration was higher in ALDH2*2 DM mice compared to C57BL DM. Increase in cardiac hypertrophy (207 ± 8, 355 ± 4, 289 ± 22, 370 ± 20 in μm2; $$P&lt;0.01 ALDH2*2 DM vs C57 DM) and fibrosis (4 ± 0.4, 8 ± 0.5, 6 ± 0.7, 9 ± 2.3 in % area of fibrosis; $$P&lt;0.01 ALDH2*2 DM vs C57 DM) were higher in ALDH2*2 DM mice compared to C57BL DM. But the contractile function (56 ± 0.7, 54 ± 1.6, 43 ± 2.7, 48 ± 1.8 in %FS; $p &lt;0.05 ALDH2*2 DM vs C57 DM) was lower only in ALDH2*2 DM, not WT DM. At the molecular level, increased mitochondrial DNA (mtDNA) damage and resultant decrease in MtDNA-encoded respiratory complex proteins were potentiated in diabetic ALDH2*2 mice compared to C57BL DM mice. Based on our data, we conclude that reduced ALDH2 activity in ALDH2*2 mice aggravated diabetes-induced cardiac mitochondrial respiratory dysfunction, ventricular remodeling and dysfunction.
West Nile virus surveillance in Europe: moving towards an integrated animal-human-vector approach
Authors: Céline M Gossner, Laurence Marrama, Marianne Carson, Franz Allerberger, Paolo Calistri, Dimitrios Dilaveris, Sylvie Lecollinet, Dilys Morgan, Norbert Nowotny, Marie-Claire Paty, Danai Pervanidou, Caterina Rizzo, Helen Roberts, Friedrich Schmoll, Wim Van Bortel, Andrea Gervelmeyer
Journal: Eurosurveillance (2017)

This article uses the experience of five European countries to review the integrated approaches (human, animal and vector) for surveillance and monitoring of West Nile virus (WNV) at national and European levels. The epidemiological situation of West Nile fever in Europe is heterogeneous. No model of surveillance and monitoring fits all, hence this article merely encourages countries to implement the integrated approach that meets their needs. Integration of surveillance and monitoring activities conducted by the public health authorities, the animal health authorities and the authorities in charge of vector surveillance and control should improve efficiency and save resources by implementing targeted measures. The creation of a formal interagency working group is identified as a crucial step towards integration. Blood safety is a key incentive for public health authorities to allocate sufficient resources for WNV surveillance, while the facts that an effective vaccine is available for horses and that most infected animals remain asymptomatic make the disease a lesser priority for animal health authorities. The examples described here can support other European countries wishing to strengthen their WNV surveillance or preparedness, and also serve as a model for surveillance and monitoring of other (vector-borne) zoonotic infections.
Four weeks of Ledipasvir/Sofosbuvir + Ribavirin with or without interferon gives very high and sustained cure rates in difficult to reach but easy to treat injecting drug users with chronic hepatitis C: final results of the 4WIDUC study
Authors: A.L.H. Oevrehus, H. Krarup, I. Birkemose, B. Mössner, P.B. Christensen
Journal: Journal of Hepatology (2017)
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
Authors: Alessandro Gronchi, Stefano Ferrari, Vittorio Quagliuolo, Javier Martin Broto, Antonio Lopez Pousa, Giovanni Grignani, Umberto Basso, Jean-Yves Blay, Oscar Tendero, Robert Diaz Beveridge, Virginia Ferraresi, Iwona Lugowska, Domenico Franco Merlo, Valeria Fontana, Emanuela Marchesi, Davide Maria Donati, Elena Palassini, Emanuela Palmerini, Rita De Sanctis, Carlo Morosi, Silvia Stacchiotti, Silvia Bagué, Jean Michelle Coindre, Angelo Paolo Dei Tos, Piero Picci, Paolo Bruzzi, Paolo Giovanni Casali
Journal: The Lancet Oncology (2017)
Efficacy and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir with ribavirin in adults with genotype 1 or genotype 4 chronic hepatitis C virus infection and child-pugh B decompensated cirrhosis
Authors: P. Mantry, R. Reddy, E. Cohen, G. Everson, A. Ramji, S. Zeuzem, S. Gordon, E. Yoshida, M. Sherman, L. Balart, A. Baumgarten, S. Lee, L.M. Fredrick, M. Abunimeh, D.E. Cohen, N.S. Shulman, J. Wilson
Journal: Journal of Hepatology (2017)
Efficacy and safety of paritaprevir/ritonavir, ombitasvir and dasabuvir plus/minus ribavirin for treatment of hepatitis C virus genotype 1b compensated cirrhosis in patients aged 70 years or older
Authors: A. Trifan, C.C. Prelipcean, L. Gheorghe, M.G. Curescu, C. Brisc, S. Bataga, E. Miftode, V. Arama, S.A. Chiriac, T. Cuciureanu, I. Sporea, A. Goldis, A. Popescu, S. Iacob, C. Cojocariu, G. Stefanescu, I. Girleanu, C. Mihai, I. Ciortescu, C. Stanciu
Journal: Journal of Hepatology (2017)
Prevention of chemotherapy-induced damage to ovarian reserve by sphingosine-1-phosphate
Authors: Fang LI, Enis Ozkaya, Komala Akula, Petra Desutter, Kutluk Oktay
Journal: Journal of Clinical Oncology (2012)

1097 Background: Chemotherapy agents such as cyclophosphamide (Cy) and doxorubicin (D) are known to compromise ovarian function. We have previously shown that these agents alter ovarian function by causing apoptotic death of primordial follicles and thereby causing diminishment of ovarian reserve (Cancer Research 2007; Aging 2011). While assisted reproduction techniques exist to preserve fertility there has been no proven approach to pharmacologic preservation of ovarian function. Sphingosine-1-Phosphate (S1P) is a naturally occurring ceramide-induced death pathway inhibitor. Here we investigated whether S1P can prevent Cy or D-induced apoptotic follicle death in mouse ovaries. Methods: Eight wk old NOD mice (n=23) were treated with Cy (75 mg/kg), Cy+S1P (200 μM), D (10 mg/kg), D+S1P or vehicle only (Control). S1P was administered via continuous infusion using a mini-osmotic pump beginning 3 hours prior to single dose chemotherapy injection for 72 hours. Ovaries were removed 72h later and serially sectioned, and stained with anti-caspase 3 (AC-3) antibody for the detection of apoptosis in primordial follicles. The ratio of apoptotic to total follicles was expressed as percentage in each group. Results: Both Cy and D resulted in significant increase in apoptotic follicle death compared to controls (48.2±11.6 vs. 28.2±8.9, p=0.016 and 46.4±5.4 vs. 24.8±5.2, p=0.004, respectively). Percentages of apoptotic follicles were similar between Cy and D-treated groups (48.2±11.6 vs. 46.4±5.4, P=NS) indicating that these agents were equally gonadotoxic. S1P treatment resulted in a significant decrease in the percentage of apoptotic follicles both in the Cy (25.6±3.5, P&lt;0.011) and the D group (32.2±10.8, P&lt; 0.013) compared to controls. In the S1P-treated groups, the percentages of apoptotic follicles were similar to those in untreated controls indicating that S1P completely blocked Cy and D-induced apoptotic follicle death. Conclusions: S1P can block apoptotic follicle death induced by highly cytotoxics agents. In addition, we showed that S1P can block follicle death by chemotherapy agents that act through different molecular mechanisms. If targeted delivery systems can be developed, S1P may hold significant promise in preserving fertility by pharmacological means.
Sustained viral response following treatment with direct acting antiviral agents for chronic hepatitis C and the risk of hepatocellular carcinoma
Authors: K.R. Reddy, M. Bourliere, K. Agarwal, E. Lawitz, A. Osinusi, K. Kersey, G. Crans, S. Moody, L. Ni, D.M. Brainard, J.G. McHutchison, A.J. Muir, M. Buti
Journal: Journal of Hepatology (2017)
Resistance selection using glecaprevir and pibrentasvir in replicons of major hepatitis C virus genotypes
Authors: T. Ng, L. Lu, T. Reisch, P. Krishnan, G. Schnell, R. Tripathi, J. Beyer, T. Dekhtyar, M. Irvin, T. Pilot-Matias, C. Collins
Journal: Journal of Hepatology (2017)
Real-world effectiveness of sofosbuvir and ledipasvir/sofosbuvir based regimens in hepatitis C virus genotype 3 infection within national hepatitis C elimination program in the country of Georgia
Authors: T. Tsertsvadze, N. Chkhartishvili, L. Sharvadze, A. Abutidze, S. Arora, K. Thornton, V. Kerashvili, M. Zhamutashvili, M. Ezugbaia, M. Svanidze, M. Darakhvelidze, V. Kvaratskhelia, N. Afdhal, S. Zeuzem
Journal: Journal of Hepatology (2017)
Prompt initiation of intravenous corticosteroids prevents deterioration of acute/severe autoimmune hepatitis (AS-AIH) and the need for liver transplantation (LT)
Authors: K. Zachou, P. Arvaniti, N.K. Gatselis, K. Azariadi, G.K. Koukoulis, G.N. Dalekos
Journal: Journal of Hepatology (2017)
SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy
Authors: J. Grebely, I.M. Jacobson, Z. Kayali, E.C. Verna, M.L. Shiffman, R.H. Hyland, L.M. Stamm, K.C. Huang, D.M. Brainard, J.G. McHutchison, S. Pol, R.T. Chung, D.E. Bernstein, G. Dore
Journal: Journal of Hepatology (2017)
Abstract 17047: Pathophysiologic Progression From the Second to Third Trimester in Fetuses With Ebstein's Anomaly or Tricuspid Valve Dysplasia: Are Early Echocardiographic Features Reliable Indicators of Late Gestation Status?
Authors: Elif Seda Selamet Tierney, Doff B McElhinney, Lindsay R Freud, Wayne Tworetzky, Bettina Cueno, Maria C Escobar-Diaz, Catherine Ikemba, Brian T Kalish, Rukmini Komarlu, Stephanie Levasseur, Michael D Puchalski, Gary M Satou, Norman H Silverman, Anita J Moon-Grady
Journal: Circulation (2015)

Background: Ebstein’s anomaly and tricuspid valve dysplasia (EA/TVD) are associated with high perinatal mortality. Poor hemodynamic status in both early and late gestation is associated with worse outcome. However, it is not known whether EA/TVD fetuses with more favorable physiology earlier in gestation progress to more severe disease in 3 rd trimester. The goal of this study was to evaluate whether initial echocardiographic indices in fetuses with EA/TVD presenting at gestational age (GA) &lt;24 wks are reliable indicators of physiologic status later in pregnancy. Methods: This multi-center, retrospective study included fetuses diagnosed with EA/TVD from 2005-11 at 23 centers. Patients with initial diagnosis at &lt;24 wks gestation and with ≥2 fetal echocardiograms ≥4 wks apart were included. A core laboratory analyzed the echocardiograms. Markers of poor outcome were defined as absence of antegrade flow across the pulmonary valve, pulmonary valve regurgitation (PR), cardiothoracic ratio &gt;0.48, left ventricular (LV) dysfunction or TV annulus Z score &gt;5.6. Results: The study included 51 fetuses. Median GA at diagnosis was 21 wks [18-24], and the median duration from 2 nd to 3 rd trimester echocardiograms was 12 wks [4-18]. There were 21 fetuses (41%) with &gt;2 markers of poor outcome at &lt;24 wks, which increased to 32 (63%) in later gestation (p=0.001). Nine of 27 fetuses (33%) with antegrade pulmonary blood flow on first echocardiogram developed anatomic or functional pulmonary atresia during follow-up, and 7 of 39 fetuses (18%) without PR initially developed it later. LV dysfunction was present in 2 patients at &lt;24 wks but present in 14 (37%) later (p&lt;0.01). The only variable associated with worsening physiology, from &lt;2 markers of poor outcome in 2 nd trimester to ≥2 markers in 3 rd trimester, was larger TV annulus Z-score (4.1±1.0 vs. 2.4±1.9, p=0.008). Conclusion: These results confirm a wide spectrum of disease presentation and progression in fetuses with EA/TVD. Thus, it is imperative to assess these fetuses serially. In this cohort, there were no early markers of progression other than larger TV annulus Z-score. Great care must be taken in counseling prior to 24 wks, as the absence of factors associated with poor outcome early in pregnancy may be falsely reassuring.
Fontan-associated liver disease: diagnosis by elastography and laparoscopic liver biopsy
Authors: Y. Koizumi, M. Hirooka, A. Yukimoto, Y. Imai, Y. Nakamura, T. Watanabe, O. Yoshida, Y. Tokumoto, T. Higaki, M. Abe, Y. Hiasa
Journal: Journal of Hepatology (2017)
Potential viral triggers for pediatric and adult autoimmune hepatitis
Authors: R. Taubert, J. Diestelhorst, N. Junge, M. Kirstein, S. Pischke, A. Vogel, H. Bantel, U. Baumann, M.P. Manns, H. Wedemeyer, E. Jaeckel
Journal: Journal of Hepatology (2017)
Efficacy and safety of ledipasvir/sofosbuvir, with or without ribavirin, for treatment of hepatitis C virus-mono and HCV/HIV co-infected patients who have failed prior treatment with non-NS5A, SOF-based therapies
Authors: E. Tam, R.S. Brown, S. Satapathy, X. Shen, G. Camus, A. Copans, L. Rossaro, W. Guyer, R. Haubrich, J. Kiser, M. Kang, T. Umbleja, A. Luetkemeyer
Journal: Journal of Hepatology (2017)
Does Sofosbuvir (SOF)/Velpatasvir (VEL) with or without Ribavirin (RBV) change the landscape of therapy in chronic hepatitis C genotype 3 (GT 3) infection? – Results from the GErman hepatitis C COhort (GECCO)
Authors: S. Christensen, P. Ingiliz, K. Schewe, J. Rockstroh, D. Hueppe, A. Baumgarten, T. Lutz, G. Schmutz, F. Berger, T. Kimhofer, H. Busch, S. Mauss
Journal: Journal of Hepatology (2017)
CRIPTO expression in hepatocellular carcinoma
Authors: D. van der Helm, S. Karkampouna, H. Verspaget, A.F. Sarasqueta, L. Chen, S. Osanto, M. Burgmans, A. Schaapherder, E. Snaar-Jagalska, B. van Hoek, L. Terracciano, M.K. de Julio, M. Coenraad
Journal: Journal of Hepatology (2017)
No increase in the occurrence rate of hepatocellular carcinoma in Chinese treated by direct-acting antivirals compared to Interferon after eradication of hepatitis c virus: a long-term follow-up
Authors: D. Ji, C. Wang, Q. Shao, F. Li, B. Li, V. Wu, A. Wong, Y.D. Wang, J. Chen, G.F. Chen, G. Lau
Journal: Journal of Hepatology (2017)
Dual targeting of vascular endothelial growth factor-A (VEGF-A) and angiopoietins (Ang) without chemotherapy in metastatic colorectal cancer (mCRC): Results of the VENGEANCE study.
Authors: Jennifer Mooi, Geoffrey Chong, Stephen Brown, Rachel Wong, Timothy Jay Price, Effie Skrinos, Niall C. Tebbutt
Journal: Journal of Clinical Oncology (2015)

3533 Background: VEGF-A and Ang play complementary roles in regulation of blood vessel growth, maturation and function. Hence we postulate that combined blockade of VEGF-A and Ang would have clinical activity in mCRC. Trebananib/AMG386 (Treb) is a peptibody that inhibits binding of Ang 1/2 to the Tie2 receptor. Previous studies have established the safety of Treb with various VEGF inhibitors including bevacizumab (Bev). Methods: VENGEANCE is an open label Phase II study evaluating the combination of Bev and Treb without chemotherapy as 1st line treatment of mCRC. Key eligibility criteria: patients (pts) with unresectable mCRC, no prior therapy, PS 0-2, adequate organ function, and in whom investigator considers not requiring immediate cytotoxic chemotherapy. Treatment: Bev 7.5mg/kg q3w and Treb 15 mg/kg qw. Primary endpoint: disease control rate (pts without disease progression, i.e. RECIST CR+PR+SD) at 6 mths (DC6m). 2 stage Simon design required stage I: DC6m >5/17 pts, stage II: DC6m >13 pts, for a positive study. Secondary endpoints: response rate (RR), toxicity, progression-free survival (PFS) and overall survival (OS). Results: 45 pts were enrolled from 4 Australian sites from Sep 2010 to Aug 2013. Med follow up is 33.7 mths. At time of analysis, 7 pts remain on study treatment (3 PR, 4 SD; duration on study 19 – 32 mths). Key AEs of interest were GI hemorrhage, TIA, cardiac ischemia, PE, GI perforation and CNS hemorrhage (2% each) and g3 hypertension (4%). Conclusions: Treb plus Bev showed promising activity that merits evaluation in further randomized studies, including combinations with chemotherapy. RR of the combination is greater than previously reported for Bev monotherapy (3%).The toxicity profile is manageable and the combination does not appear to increase toxicities in excess of those expected with Bev +/-chemotherapy. Clinical trial information: NCT01249521.Endpoint outcomes. DC6m ORR Med PFS (mths)* Med OS (mths)* Treb + Bev (N=45) 60 % (n=27 non-PD, n=18 PD) 15.5% (n=7 PR, no CR) 9.0 (6.5 – 12.8) 33.4 (27.1 – 39.5) *Kaplan-Meier estimates, with 95% confidence intervals